10% Owner Sells $5.8M in Theravance Biopharma Shares Post-Acquisition Announcement
TBPH sits 56% above its 52-week low of $10.822 on elevated volume (2.6× avg).
Summary
A 10% owner sold $5.79 million in Theravance Biopharma shares following the announcement of the company's acquisition by Zymeworks.
Key Events · Ownership and Investor Activity · TBPH
-
Significant Insider Sale
Eli Samaha, a 10% owner, disposed of 336,697 shares for a total value of $5,791,555 through open market sales.
-
Post-Acquisition Liquidation
The sales occurred between June 29 and July 1, at prices ranging from $17.00 to $17.23, immediately after the June 29 announcement of Theravance Biopharma's acquisition by Zymeworks for $17.00 per share in cash.
-
Reduced Ownership Stake
These transactions reduced the reporting owner's indirect holdings to 9,174,453 shares.
Analysis · TBPH · Life Sciences
Eli Samaha, a 10% owner, sold $5.79 million worth of shares in Theravance Biopharma. These sales occurred between June 29 and July 1, immediately following the June 29 announcement that the company would be acquired by Zymeworks for $17.00 per share in cash. The sales were executed at prices at or slightly above the announced cash acquisition price, indicating a liquidation of holdings by the 10% owner in anticipation of the merger.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TBPH was trading at $16.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $875.4M. The 52-week trading range was $10.82 to $21.03. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.